Pertuzumab is a recombinant monoclonal antibody that acts as an antineoplastic agent, which targets the human epidermal growth factor receptor 2 protein known as HER2. The drug blocks signaling pathways that leads to cell growth arrest and apoptosis (cell destruction), thereby inhibiting the proliferation of human tumor cells. Pertuzumab was found to aid in the treatment of HER2 associated breast cancer and was developed by Genentech, Inc., a subsidiary of F. Hoffmann-La Roche AG. It was first approved by U.S. Food and Drug Administration in 2012.
Pertuzumab Market– Drivers
There are increasing number of clinical trials for use of pertuzumab in combination with other drugs for the treatment of breast cancer . For instance, Helsinki University Central Hospital is undergoing phase III clinical study for adjuvant trastuzumab, pertuzumab, and docetaxel in the treatment of early HER2 positive breast cancer. The study was started in December 2015 and is estimated to complete by June 2023.
Furthermore, increasing number of drug approvals are expected to propel growth of the global pertuzumab market. For instance, in December 2017, the U.S. Food and Drug Administration (U.S FDA) granted approval to PERJETA, a pertuzumab produced by Genentech, Inc. for its use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.
Moreover, development of novel anticancer drug delivery technologies is expected to boost growth of the market. For instance, in July 2018, Gentech, Inc., in partnership with Halozyme Therapeutics, Inc., used proprietary ENHANZE drug-delivery technology of Halozyme Therapeutics, Inc., for subcutaneous administration of fixed-dose combination of pertuzumab (PERJETA) and trastuzumab (Herceptin). This study is under clinical phase III trial. ENHANZE technology aids in reducing the need for multiple injections and reduces time required for drug administration.
Pertuzumab Market– Restraint
Increasing cost of anticancer drugs is expected to be a major factor hampering growth of the market. For instance, in June 2017, The Scottish Medicines Consortium (SMC) denied access to pertuzumab in England, which was available via the Cancer Drugs Fund (CDF) in Europe. The drug was rejected by SMC as the treatment of HER2 positive breast cancer was not cost effective when pertuzumab was used in combination with trastuzumab and docetaxel.
Request Free PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2256
Moreover, according to a study published in the journal Oncology, September 2015, although the use of pertuzumab with docetaxel and trastuzumab as first-line therapy for HER2 positive breast cancer has been shown to yield a substantial survival benefit, the therapy is not cost effective in the U.S. Also, according to the same source, the cost of treating HER2 positive breast cancer with pertuzumab and other drugs is US$ 509,845 and that with only docetaxel and trastuzumab is US$ 135,092.
Pertuzumab Market– Regional Analysis
On the basis of region, the global pertuzumab market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global pertuzumab market due to increasing prevalence of breast cancer among women in the U.S. For instance, according to American Cancer Society 2017, around 52,710 new cases of invasive breast cancer were diagnosed in 2017 among women in the U.S. and around 40,610 women were expected to die due to breast cancer in the U.S. in same year.
Furthermore, Asia Pacific is expected to witness significant growth in the global pertuzumab market, owing to increasing awareness of breast cancer and its management. For instance, in November 2016, India launched National Cancer Screening Program to increase awareness and early detection of breast cancer. This framework aims to offer mechanism for effective screening and management of common cancers.
Pertuzumab market – Competitive Analysis
Key players operating in the global pertuzumab market include, Halozyme Therapeutics, Inc. and F. Hoffmann-La Roche Ltd.
Pertuzumab Market Taxonomy:
- By Indication
- Early Breast Cancer
- Metastatic Breast Cancer
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Browse Full Report Details @ https://www.coherentmarketinsights.com/ongoing-insight/pertuzumab-market-2256
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Name: Mr. Raj Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
Your information will never be shared with any third party.